These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 20603656)

  • 1. Molecule of the month. Telaprevir.
    Drug News Perspect; 2010 Jun; 23(5):329. PubMed ID: 20603656
    [No Abstract]   [Full Text] [Related]  

  • 2. Trial watch: Protease inhibitors show promise against HCV.
    Nat Rev Drug Discov; 2009 Jan; 8(1):11. PubMed ID: 19116621
    [No Abstract]   [Full Text] [Related]  

  • 3. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
    Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G
    Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blunting the Swiss army knife of hepatitis C virus: inhibitors of NS3/4A protease.
    White PW; Llinas-Brunet M; Bös M
    Prog Med Chem; 2006; 44():65-107. PubMed ID: 16697895
    [No Abstract]   [Full Text] [Related]  

  • 5. Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.
    Suzuki F; Suzuki Y; Akuta N; Sezaki H; Yatsuji H; Arase Y; Hirakawa M; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Iwasaki S; Kumada H
    J Clin Virol; 2010 Jan; 47(1):76-8. PubMed ID: 19857995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to overcome antiviral-resistant hepatitis B virus?
    Song BC
    Intervirology; 2010; 53(1):29-38. PubMed ID: 20068338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telaprevir: hope on the horizon, getting closer.
    Weisberg IS; Jacobson IM
    Clin Liver Dis; 2009 Aug; 13(3):441-52. PubMed ID: 19628160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serine protease inhibitors as anti-hepatitis C virus agents.
    Reiser M; Timm J
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):537-47. PubMed ID: 19485794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats.
    Maltais F; Jung YC; Chen M; Tanoury J; Perni RB; Mani N; Laitinen L; Huang H; Liao S; Gao H; Tsao H; Block E; Ma C; Shawgo RS; Town C; Brummel CL; Howe D; Pazhanisamy S; Raybuck S; Namchuk M; Bennani YL
    J Med Chem; 2009 Dec; 52(24):7993-8001. PubMed ID: 19894743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Strong reasons make strong actions"--The antiviral efficacy of NS3/4A protease inhibitors.
    Lemon SM; Yi M; Li K
    Hepatology; 2005 Mar; 41(3):671-4. PubMed ID: 15723328
    [No Abstract]   [Full Text] [Related]  

  • 11. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.
    Boloor A; Hanway D; Joshi M; Winn DT; Mendez G; Walls M; Wei P; Qian F; Zhang X; Zhang Y; Hepperle ME; Li X; Campbell DA; Betancort JM
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5708-11. PubMed ID: 19713109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial: Towards the eradication of hepatitis C virus.
    Marcellin P; Asselah T
    Liver Int; 2012 Feb; 32 Suppl 1():1. PubMed ID: 22212564
    [No Abstract]   [Full Text] [Related]  

  • 13. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.
    McCauley JA; Rudd MT; Nguyen KT; McIntyre CJ; Romano JJ; Bush KJ; Varga SL; Ross CW; Carroll SS; DiMuzio J; Stahlhut MW; Olsen DB; Lyle TA; Vacca JP; Liverton NJ
    Angew Chem Int Ed Engl; 2008; 47(47):9104-7. PubMed ID: 18925594
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis.
    Soriano V; Barreiro P; Martín-Carbonero L; Castellares C; Ruiz-Sancho A; Labarga P; Ramos B; Gonzalez-Lahoz J
    J Infect Dis; 2007 Apr; 195(8):1181-3. PubMed ID: 17357055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe cutaneous eruptions on telaprevir.
    Chen ST; Wu PA
    J Hepatol; 2012 Aug; 57(2):470-2. PubMed ID: 22387663
    [No Abstract]   [Full Text] [Related]  

  • 16. [Chronic hepatitis C: current treatment and perspectives].
    Negro F
    Rev Med Suisse; 2011 Jan; 7(279):212-3. PubMed ID: 21387717
    [No Abstract]   [Full Text] [Related]  

  • 17. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleotide analogs as novel anti-hepatitis B virus agents.
    Iyer RP; Padmanabhan S; Zhang G; Morrey JD; Korba BE
    Curr Opin Pharmacol; 2005 Oct; 5(5):520-8. PubMed ID: 16087397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection.
    Hofmann WP; Soriano V; Zeuzem S
    Handb Exp Pharmacol; 2009; (189):321-46. PubMed ID: 19048206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
    Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.